MedTrace Logo

Evaluation of HQ® Matrix Soft Tissue Mesh for the Treatment of Inguinal Hernia

NCT02487628 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2015-07-01

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and effectiveness of HQ® Matrix Soft Tissue Mesh for the Treatment of Inguinal Hernia. Half of participants will receive HQ® Matrix Soft Tissue Mesh, while the other half will receive ULTRAPRO® Partially Absorbable Lightweight Mesh.

Conditions

  • Inguinal Hernia

Interventions

DEVICE

HQ® Matrix Soft Tissue Mesh

DEVICE

ULTRAPRO® Partially Absorbable Lightweight Mesh

Sponsors & Collaborators

  • Zhejiang Xingyue Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianhua Huang · Xiangya Hospital of Centre-South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02487628 on ClinicalTrials.gov